Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Accumulated Expenses (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Accumulated Expenses for 5 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 13.06% year-over-year to $13.5 million, compared with a TTM value of $13.5 million through Dec 2025, down 13.06%, and an annual FY2025 reading of $13.5 million, down 13.06% over the prior year.
  • Accumulated Expenses was $13.5 million for Q4 2025 at Aligos Therapeutics, up from $11.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $22.8 million in Q3 2021 and bottomed at $3.1 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $9.5 million, with a median of $6.5 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses plummeted 83.96% in 2023, then skyrocketed 259.74% in 2025.
  • Year by year, Accumulated Expenses stood at $6.3 million in 2021, then dropped by 0.51% to $6.3 million in 2022, then increased by 5.97% to $6.7 million in 2023, then skyrocketed by 133.13% to $15.6 million in 2024, then fell by 13.06% to $13.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for ALGS at $13.5 million in Q4 2025, $11.0 million in Q1 2025, and $15.6 million in Q4 2024.